G. Paul Amminger

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra‐high risk in the <scp>UHR</scp> 1000+ cohort

Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis

Serum immune markers and transition to psychosis in individuals at clinical high risk

A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis

Development of the <scp>PSYCHS</scp> : Positive SYmptoms and Diagnostic Criteria for the <scp>CAARMS</scp> Harmonized with the <scp>SIPS</scp>

Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People

Neuroanatomical heterogeneity and homogeneity in individuals at clinical high risk for psychosis

Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis

Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis

Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence

Neuroharmony: A new tool for harmonizing volumetric MRI data from unseen scanners

Dysregulated Lipid Metabolism Precedes Onset of Psychosis

Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course

Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder

PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia

Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders

Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis

Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk

NEURAPRO‐E study protocol: a multicentre randomized controlled trial of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders

Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids

Biomarkers and clinical staging in psychiatry